Pentoxifylline tablets 100mg, No. 60
Expiration Date: 11/2025
Russian Pharmacy name:
Пентоксифиллин таблетки 100мг, №60
disorders of peripheral circulation of atherosclerotic genesis (for example, 'intermittent' claudication, diabetic angiopathy), trophic disorders (for example, trophic ulcer of the leg, gangrene); frostbite, post-thrombotic syndrome, etc. (when using solution for infusion);
cerebral circulation disorders (consequences of cerebral atherosclerosis, such as impaired concentration, dizziness, memory impairment), ischemic and post-stroke conditions;
circulatory disorders in the retina and choroid;
otosclerosis, degenerative changes against the background of vascular pathology of the inner ear and hearing loss.
TrentalЃ
TrentalЃ 400
Tablets 100, 400 mg
The dosage is set by the doctor in accordance with the individual characteristics of the patient.
Inside, swallowing whole, during or immediately after a meal, drinking plenty of water.
The usual dose is 1 table. TrentalЃ 100 mg 3 times a day, followed by a slow increase in the dose to 200 mg 2-3 times a day. The maximum single dose is 400 mg.
The usual dose is 1 table. TrentalЃ 400 mg 2-3 times a day.
The maximum daily dose is 1200 mg. In patients with impaired renal function (Cl creatinine <30 ml / min), the dosage can be reduced to 1-2 tablets. per day.
TrentalЃ
Solution for infusion
The dosage is set by the doctor in accordance with the individual characteristics of the patient.
IV, drip, dose and route of administration are determined by the severity of circulatory disorders, as well as on the basis of the individual tolerance of the drug.
The usual dose is two intravenous infusions per day (morning and afternoon), each containing 200 mg of pentoxifylline (2 amp. 5 ml) or 300 mg of pentoxifylline (3 amp. 5 ml) in 250 ml or 500 ml 0 , 9% sodium chloride solution or Ringer's solution. Compatibility with other infusion solutions must be tested separately; only clear solutions can be used.
Pentoxifylline (100 mg) should be administered over at least 60 minutes. Depending on the concomitant diseases (heart failure), it may be necessary to reduce the volume injected. In such cases, it is recommended to use a dedicated infuser for controlled infusion.
After the daily infusion, an additional 2 tablets may be prescribed. TrentalЃ 400 mg. If 2 infusions are separated by a longer interval, then 1 table. Trental 400 mg of the additionally prescribed two, can be taken earlier (at about noon).
If, due to clinical conditions, it is possible to perform intravenous infusion only once a day, in addition, 3 tables can be prescribed after it. TrentalЃ 400 mg (at noon - 2 tablets and in the evening - 1 table). Long-term intravenous infusion of Trental - within 24 hours is indicated in more severe cases, especially in patients with severe pain at rest, with gangrene or trophic ulcers (III-IV stages according to Fontaine).
The dose of TrentalЃ administered parenterally over 24 hours, as a rule, should not exceed 1200 mg of pentoxifylline, while the individual dose can be calculated using the formula: 0.6 mg of pentoxifylline per kg of body weight per hour. The daily dose calculated in this way will be 1000 mg of pentoxifylline for a patient weighing 70 kg and 1150 mg of pentoxifylline for a patient weighing 80 kg. In patients with renal insufficiency (Cl creatinine <30 ml / min), it is necessary to reduce the dosage by 30-50%, which depends on the individual patient's tolerance of the drug.
For all dosage forms, the dosage is set by the doctor in accordance with the individual characteristics of the patient. A dose reduction, taking into account individual tolerance, is necessary in patients with severe hepatic impairment. Treatment can be started with low doses in patients with low blood pressure, as well as in those at risk due to a possible decrease in blood pressure (patients with severe coronary artery disease or hemodynamically significant cerebral vascular stenosis). In these cases, the dose can only be increased gradually.
TrentalЃ
Intestinal film-coated tablets | 1 tab. |
active substance: | |
pentoxifylline | 100 mg |
excipients: lactose; starch; talc; colloidal silicon dioxide; magnesium stearate | |
shell: methacrylic acid copolymer; sodium hydroxide; macrogol (polyethylene glycol) 8000; talc; titanium dioxide (E171) |
Concentrate for solution for infusion | 1 ml |
active substance: | |
pentoxifylline | 20 mg |
excipients: sodium chloride; water for injections |
TrentalЃ 400
Sustained-release film-coated tablets | 1 tab. |
active substance: | |
pentoxifylline | 400 mg |
excipients: povidone (PVP); hyetellose (hydroxyethyl cellulose); talc; magnesium stearate | |
film shell: hypromellose (hydroxypropyl methylcellulose); benzyl alcohol; titanium dioxide; talc; macrogol (polyethylene glycol) 6000 |
Tablets 100 mg and 400 mg
hypersensitivity to pentoxifylline, other methylxanthines, or to any of the components of the drug;
massive bleeding, extensive retinal hemorrhage, cerebral hemorrhage;
acute myocardial infarction;
pregnancy;
breastfeeding period;
children under 18 years of age.
Carefully:
severe cardiac arrhythmias (risk of worsening arrhythmias);
arterial hypotension (risk of further lowering blood pressure, see the section 'Dosage and Administration');
chronic heart failure;
peptic ulcer of the stomach and duodenum;
impaired renal function (Cl creatinine below 30 ml / min) (risk of accumulation and increased risk of side effects, see section 'Dosage and Administration');
severe liver dysfunctions (risk of accumulation and increased risk of side effects, see section 'Method of administration and dosage');
after recently undergone surgical interventions;
an increased tendency to bleeding, for example, as a result of the use of anticoagulants or in case of disorders in the blood coagulation system (the risk of developing more severe bleeding).
Solution for infusion
hypersensitivity to pentoxifylline, other methylxanthines, or to any of the components of the drug;
massive bleeding, extensive retinal hemorrhage, cerebral hemorrhage;
acute myocardial infarction;
severe arrhythmias;
severe atherosclerotic lesions of the coronary or cerebral arteries;
uncontrolled arterial hypotension;
pregnancy;
breastfeeding period;
children under 18 years of age.
Carefully:
arterial hypotension (risk of lowering blood pressure);
chronic heart failure;
impaired renal function (Cl creatinine below 30 ml / min) (risk of cumulation and increased risk of side effects);
severe liver dysfunction (risk of cumulation and increased risk of side effects);
increased tendency to bleeding, incl. as a result of the use of anticoagulants or in case of disorders in the blood coagulation system (the risk of developing more severe bleeding);
after recently undergone surgical interventions.